Pharmaceutical firms are at the forefront of the battle against COVID-19 and are experiencing strong progress on the capital exchange and a fresh surge of creativity in the world of communicable diseases when the drug acceptance sprint for COVID-19therapy continues.
Shares in Chongqing Zhifei Biological Products Co. have risen by 80 percent since the vaccine manufacturer announced at the end of June that a COVID-19 vaccine was licensed by China’s drug regulator for clinical human trials.
Profits also driven the fortune of Jiang Rensheng, Zhifei ‘s chairman, to $19.4 billion, bringing him close to joining China’s 10 wealthiest people’s elite community, run by software and real estate moguls.
The Jiang Rensheng, chairman of Zhifei, net worth more than doubled in July itself, the highest increase of the world’s 500 richest men, and this year is up $14.4 billion. Jiang, 66, owns approximately 56 per cent of Zhifei.
For the first six months of 2020, Zhifei reported a net income of 1.5 billion yuan, slightly higher compared 30 percent from last year.
A 171 percent rally at Shenzhen Kangtai Biological Products Co. took the fortune of Chairman Du Weimin to $5.4 billion, although his ex-wife, Yuan Liping, is now the third-richest female in Canada with $5.5 billion.
Beijing Wantai Biological Pharmacy Enterprise Co. has soared 30-fold after a preliminary April share sale, taking its chairman ‘s wealth to $19.4 billion.
Shares for the pharmaceutical firm Moderna Inc. in the United States, which is focusing on the vaccine Covid-19, have nearly quadrupled this year.
The idea of substantial gains from recently produced drug could undergo heightened scrutiny at a period of global pandemic as a consequence of societal and economic strains.
